Neuspera Medical Secures $23M Series D Funding to Advance Ultra-Miniature Neuromodulation Implant for Urge Incontinence

Source: Siyu MedTech; Editor: Sophia

Pre-announcement: The 2nd Global Surgical Robotics Conference

Complete Review: The First Global Medical Technology Conference

This time, in addition to serving as a peripheral nerve stimulator, the NeuSpera miniaturized system is also expected to be used in sacral nerve stimulation systems to stimulate the nerves responsible for symptoms of urge incontinence, thereby providing treatment.Urgent Urinary Incontinence (UUI)。

NeuSpera Ultra-Miniature System byMicro-implantable electrodes, wearable wireless generator, clinician programmer,Mobile AppComposition (from left to right).

• Micro-implantable electrode

The micro-implantable electrode has a diameter of only 2 mm and features a modular structure, allowing the implant to adapt to various neural interfaces. It offers a range of programmable stimulation parameters, including frequency, pulse width, and amplitude (voltage) for current control, providing significant flexibility in addressing common neural stimulation applications.

• Wearable Wireless Generator

The wearable wireless generator is compact and lightweight, capable of wirelessly charging micro-implantable electrodes deeply embedded within the body, and features automatic detection (of micro-implantable electrodes and human tissue), automatic power steering, and automatic data collection.

• Smartphone Application

Patients will be able to adjust therapy settings, modulate stimulation status, and perform many other functions through a simple and intuitive smartphone app. The app can be upgraded via remote deployment.

• Clinician Programmer

iPad-Based Clinician ProgrammerProvides physicians with a “command center” view of all NeuSpera implanted devices and external wireless transmitters in their clinic.

Product Features

1. Small size, less pain

The NeuSpera ultra-miniature system is implanted on peripheral nerves outside the brain and spinal cord,Intercepts pain signals traveling along nerves by delivering electrical pulses, thereby alleviating the body's perception of pain.

NeuSpera’s ultra-miniaturized system occupies approximately 75 times less space than other PNS devices, enabling physicians to access a broader range of peripheral nervous system regions than is possible with larger implants, thereby alleviating patient pain.

2. Mid-field Power Transmission Technology

The NeuSpera system hasMidfield Powering Technology Patent: Utilizes transient and propagating electromagnetic waves to power implantable medical devices, achieving depths of 10 centimeters or greater. The system leverages the body as a natural waveguide to concentrate energy, ensuring precise delivery to the target area.

3. No Need for Frequent Battery Replacement

The NeuSpera microminiature system integrates the receiver and pulse generator, is charged via a wireless transmitter, and delivers electrical pulses to nerves.

The transmitter is worn externally and can power the implant without direct skin contact, thereby addressing the issue of frequent battery replacements required by traditional PNS.

On December 6, 2023, NeuSpera Medical announced the completion of patient enrollment and implantation procedures for its pivotal SANS-UUI clinical trial.

# Financing History

• In 2018, NeuSpera Medical received$26 Million Series B Financing。
  ByTonghe YuchengLed by the lead investor, with all Series A investors, including Action Potential Venture Capital and Windham Venture Partners, participating in the follow-on investment;
  In addition, Data Capital and Purple Arch Ventures, as new investors, also participated in this round of financing.
  Dr. Zhu Qingsheng, Managing Partner of Tonghe Yucheng, will join the company’s Board of Directors as the representative of Series B investors.The funds raised will be used to support the research, development, and clinical trials of the company’s implantable neuromodulation technology platform.
• In 2021, NeuSpera Medical received$65 Million Series C Financing, this round of financing was co-led by Vertex Ventures HC and Treo Ventures, with existing investors including Tonghe Yucheng also participating in the follow-on investment.
  The Company will use the proceeds from this financing to conduct clinical studies on its ultra-small implantable neuromodulation platform for the treatment of urgency urinary incontinence associated with overactive bladder.